Transdermal Nicotine and Bupropion-SR in Schizophrenics

描述：（申请人提供） 吸烟的流行率很高（60- 88%）， 精神分裂症，但很少有戒烟干预措施已经开发出来， 对于这些患者。在这方面，控制吸烟的因素知之甚少。 或者是否采取干预措施，减少吸烟的人群中， 对一般人群吸烟者精神分裂症有效。两 在一般人群中减少吸烟的药物疗法是透皮的， 尼古丁和缓释安非他酮。因为神经化学功能紊乱 与精神分裂症相关，这些药物治疗可能对 患有精神分裂症的吸烟者临床和实验研究， 精神分裂症吸烟者的尼古丁替代治疗产生了模棱两可的结果， 结果一项单次治疗研究的初步结果， 释放安非他酮似乎有希望。本建议中的研究包括 在受控的实验室条件下， 透皮尼古丁（0、21、42毫克/天）和缓释安非他酮（0， 150，300毫克/天）对吸烟的人与精神分裂症和非精神分裂症 对照尼古丁和安非他酮缓释剂经皮给药的效果 吸烟地形测量、吸烟欲望、尼古丁戒断症状和 影响将被确定。这些研究使用受试者内，重复 措施，安慰剂对照设计。它们将共同提供急需的 关于透皮给药的生物学、行为学和主观效应的信息 尼古丁和缓释安非他酮对吸烟者的影响 精神分裂症反过来，这些信息可以有助于发展 有效的戒烟治疗吸烟者与精神分裂症。

DESCRIPTION: (provided by applicant) There is a high prevalence (60-88 percent) of cigarette smoking among people with schizophrenia, but few smoking cessation interventions have been developed for these patients. Little is known about factors that control smoking in this population or whether interventions that reduce cigarette smoking among the general population are effective in smokers with schizophrenia. Two pharmacotherapies that reduce smoking in the general population are transdermal nicotine and sustained release bupropion. Because of neurochemical dysfunction associated with schizophrenia, these pharmacotherapies may be less effective in smokers with schizophrenia. Clinical and experimental studies on the effects of nicotine replacement in smokers with schizophrenia have yielded equivocal results. Preliminary results from a single treatment study with sustained release bupropion appear promising. The studies in the present proposal are designed to examine under controlled laboratory conditions the effects of transdermal nicotine (0, 21, 42 mg/day) and sustained release bupropion (0, 150, 300 mg/day) on smoking in people with schizophrenia and non-schizophrenic controls. The effects of transdermal nicotine and sustained release bupropion on smoking topography measures, smoking urges, nicotine withdrawal symptoms and affect will be determined. These studies use within-subjects, repeated measures, placebo controlled designs. Together, they will provide much-needed information on the biological, behavioral and subjective effects of transdermal nicotine and sustained release bupropion on smoking in people with schizophrenia. In turn, this information could contribute to the development of effective smoking cessation treatments for smokers with schizophrenia.